Cigna rolls out new plan to fully cover multi-million dollar gene therapies
A screen displays the logo fro Cigna Corp. on the floor at the New York Stock Exchange (NYSE) in New York, U.S., July 16, 2019. REUTERS/Brendan McDermid (Reuters) – Health…
Novartis, Lonza deepen biosimilars push with MS, arthritis drug deals
ZURICH (Reuters) – Swiss drugmakers Novartis and Lonza separately deepened their push into so-called biosimilars, betting cheaper copies of name-brand drugs will make headway among cost-conscious insurers and governments. Novartis’s…
UK cost watchdog recommends Novartis’ blindness therapy Luxturna
(Reuters) – Novartis AG’s gene therapy for blindness, Luxturna, is recommended for use on England’s public health service, the country’s healthcare cost-effectiveness watchdog NICE said on Tuesday. Novartis owns the…
Roche, Spark again extend $4.3 billion takeover offer
FILE PHOTO: The logo of Swiss drugmaker Roche at its headquarters in Basel, Switzerland, February 1, 2018. REUTERS/Arnd Wiegmann/File Photo ZURICH (Reuters) – Roche Holding (ROG.S) and Spark Therapeutics (ONCE.O)…
Patent court to review Alexion’s Soliris patents on Amgen challenge
(Reuters) – The U.S. patent office will review patents on Alexion Pharmaceuticals Inc’s blood disorder treatment Soliris, after Amgen Inc challenged them, court filings showed on Friday. FILE PHOTO: An…
Retrophin scraps nervous system disorder study, shares dive
(Reuters) – Retrophin Inc said on Thursday it was discontinuing the late-stage study for its rare neurological disorder treatment after it failed to improve patients’ ability to conduct daily activities…
GSK builds oncology pipeline as drug shown to help myeloma patients
(Reuters) – GlaxoSmithKline said an experimental multiple myeloma treatment has shown a meaningful response in patients that have run out of three previous treatment options, in a boost for the…
Companies file suit in Canada challenging new rules to lower drug prices
(Reuters) – Five pharmaceutical companies said on Friday they have filed a complaint in a Canadian court challenging the constitutionality of new Canadian regulations meant to lower patented drug prices,…
FDA declines to approve Sarepta’s second Duchenne treatment
(Reuters) – Sarepta Therapeutics Inc said on Monday the U.S. Food and Drug Administration declined to approve its newest treatment for Duchenne muscular dystrophy (DMD), citing safety concerns including the…
FDA approves Celgene’s bone marrow cancer treatment
(Reuters) – The U.S. Food and Drug Administration on Friday approved Celgene Corp’s Inrebic to treat certain rare forms of bone marrow cancer called myelofibrosis, making it the second approved…